Bayer Files Lawsuit Against Johnson & Johnson Over Misleading Marketing of Prostate Cancer Drug
Deep News
19 hours ago
Bayer initiated legal proceedings against Johnson & Johnson on Monday, accusing the rival pharmaceutical company of engaging in deceptive marketing practices for a prostate cancer treatment.
According to a complaint filed in Manhattan federal court, Johnson & Johnson launched a misleading promotional campaign targeting Bayer's drug Nubeqa in order to promote and exaggerate the purported advantages of its own medication, Erleada.
Bayer is seeking triple damages, the recovery of profits allegedly gained by Johnson & Johnson through improper means, and an injunction to halt what it describes as the rival's false advertising.
Johnson & Johnson has not yet issued an immediate response to requests for comment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.